Global Paroxetine Hydrochloride Tablet Market Size, Share and Trends Analysis Report, By By Application (Major Depressive Disorder (MDD), Obsessive-Compulsive Disorder (OCD), Panic Disorder (PD), Posttraumatic Stress Disorder (PTSD), Social Anxiety Disorder (SAD), Premenstrual Dysphoric Disorder (PMDD), and Generalized Anxiety Disorder), Forecast (2022-2028)

The paroxetine hydrochloride tablet market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Paroxetine Hydrochloride is an antidepressant that is used in the treatment of MDD, panic attacks, OCD, PTSD, SAD (social phobia), and a severe type of premenstrual syndrome. Mood, sleep, appetite, and energy levels are all improved with this medicine. It is been also used to reduce fear, anxiety, unpleasant thoughts, and panic attacks. This medicine lessens the desire to conduct repetitive chores that are inconvenient in everyday life. It is a selective serotonin reuptake inhibitor (SSRI) and works by assisting in the restoration of a natural substance (serotonin) equilibrium in the brain. The rising prevalence of depression and anxiety are the major factors driving the growth of the global paroxetine hydrochloride tablet market.
The market players are also contributing significantly to the market’s growth by adopting various strategies, including mergers, acquisitions, geographical expansion, partnerships, collaborations, and new product launches, to stay competitive in the market. For instance, in December 2021, Jazz Pharmaceuticals PLC announced that the first patient has been enrolled in the Phase-2 clinical trial evaluating the safety and efficacy of JZP150, an investigational first-in-class small molecule for the treatment of adults with PTSD. JZP150 is a highly selective inhibitor of the enzyme fatty acid amide hydrolase (FAAH), designed to address the underlying cause of PTSD as well as the patient’s associated symptoms (anxiety, insomnia, and nightmares). JZP150 was granted Fast Track designation by the US Food and Drug Administration (FDA) for PTSD based on the serious nature of the disorder.

Market Coverage
The market number available for – 2021-2028
Base year- 2021
Forecast period- 2022-2028

Segment Covered-
By Application

Regions Covered-
North America
Europe
Asia-Pacific
Rest of the World

Competitive Landscape-
Pfizer Inc., Cipla Inc., Teva Pharmaceutical Industries Ltd., Mylan NV, Aurobindo Pharma Ltd., Lupin Pharmaceuticals Inc., and Sun Pharmaceutical Industries Ltd., among others.

Key questions addressed by the report
What is the market growth rate?
Which segment and region dominate the market in the base year?
Which segment and region will project the fastest growth in the market?
How has COVID-19 impacted the market?
Deviation from the pre-COVID-19 forecast
Most affected region and segment
Who is the leader in the market?
How players are addressing challenges to sustain growth?
Where is the investment opportunity?

Global Paroxetine Hydrochloride Tablet Market Report by Segment
By Application
Major Depressive Disorder (MDD)
Obsessive-Compulsive Disorder (OCD)
Panic Disorder (PD)
Posttraumatic Stress Disorder (PTSD)
Social Anxiety Disorder (SAD)
Premenstrual Dysphoric Disorder (PMDD)
Generalized Anxiety Disorder